Meridian Reports 1 Percent Drop in Q1 Revenues; Mixed Results in Dx, Life Science Segments | GenomeWeb

NEW YORK (GenomeWeb News) — Meridian Bioscience today reported a 1 percent year-over-year drop in fiscal 2014 first-quarter revenues with mixed results in both its Illumigene molecular diagnostics and core life science businesses.

For the three months ended Dec. 31, Meridian reported revenues of $44.8 million, compared to $45.4 million in the year-ago period and well short of the consensus analyst estimate of $49 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.